Advancing your therapeutic mesenchymal stem cell therapy research to clinical applications requires careful material selection because the quality of starting materials significantly impact the properties of your final stem cell therapy product.
Gibco Cell Therapy Systems (CTS) products have been developed to ease the transition from stem cell therapy research to clinical applications by providing high quality GMP manufactured, commercial scale ancillary materials with a high degree of qualification, traceability and regulatory documentation. In an effort to help you maximize the potential of your adult stem cell therapy research and simplify the transition to clinic-ready processes we offer an extensive selection of research use mesenchymal stem cell research products with complementary CTS formulations for MSC clinical research and commercial applications.
CTS products are high quality and are a trusted source for MSC clinical research. Our CTS products are used in commercially approved cell therapies as well as over 200 clinical trials and are backed by our professional regulatory support and over 30 years of GMP manufacturing experience.
Mesenchymal stem cells (MSCs), also arguably known as stromal cells, are present in many tissues and are most known for their capacity to differentiate into specialized cells developing from mesoderm, namely osteoblasts, adipocytes and chondrocytes. Advancements in mesenchymal stem cell (MSC) research continue to shed light on how these multipotent stem cells may be used in various clinical applications. Preclinical and clinical adult mesenchymal stem cell therapy applications include immunomodulatory therapies (i.e., prevention of graft-versus-host disease or treatment of Crohn’s disease), autologous or allogeneic immunochemotherapies, and cell replacement therapies for mesenchymal tissues such as bone and cartilage. For more than a decade, we have provided key resources to address challenges in your stem cell workflow for your MSC clinical research. Designed to work together, our portfolio of mesenchymal stem cell products and services is designed to support and accelerate your path from discovery to the clinic.
To further help you maximize the potential of your research and streamline your transition to the clinic, we offer Gibco Cell Therapy Systems (CTS) equivalents for many of our research-use products. In addition to GMP manufacturing, CTS products undergo extensive safety testing and are accompanied by appropriate documentation so you can transition your cell therapy to the clinic with confidence.
*Adherence to supplier related responsibilities of USP<1043>
We offer full customization options to help meet your unique specifications for any project. Flexibility is yours in creating your own Gibco custom cell culture medium
See below for the extended list of reagents needed for stem cell maintenance and expansion. Gibco CTS GlutaMAX-1 is added to the Gibco CTS KnockOut SR XenoFree complete medium, and Gibco CTS TrypLE Select is an AOF reagent used for gentle cell dissociation.
A non-animal alternative for porcine trypsin, Gibco CTS TrypLE Select is a recombinant enzyme derived from microbial fermentation. The CTS product line enables you to reduce your burden in qualifying reagents during your transition from research applications to clinical applications.
Gibco CTS DPBS, without CaCl2, without MgCl2 is formulated to offer these benefits:
Gibco CTS GlutaMAX I is a dipeptide substitute for L-glutamine and can be used as a direct substitute for L-Glutamine at equimolar concentrations in mammalian and stem cell culture with minimal or no adaptation. The CTS product line enables you to reduce your burden in qualifying reagents during your transition from research applications to clinical applications.